References
- Garber K. China approves world’s first oncolytic virus therapy for cancer treatment. J. Natl Cancer Inst. 98(5), 298–300 (2006).
- Peng KW, Myers R, Greenslade A et al. Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses. Gene Ther. 20(3), 255–261 (2012).
- Kottke T, Thompson J, Diaz RM et al. Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2. Clin. Cancer Res. 15(2), 561–569 (2009).
- Fulci G, Dmitrieva N, Gianni D et al. Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res. 67(19), 9398–9406 (2007).
- Alvarez-Breckenridge CA, Yu J, Price R et al. NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nat. Med. 18(12), 1827–1834 (2012).
- Ikeda K, Wakimoto H, Ichikawa T et al. Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J. Virol. 74(10), 4765–4775 (2000).
- Yoo JY, Pradarelli J, Haseley A et al. Copper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSV. Clin. Cancer Res. 18(18), 4931–4941 (2012).
- Bonham M, O’Connor JM, Hannigan BM, Strain JJ. The immune system as a physiological indicator of marginal copper status? Br. J. Nutr. 87(5), 393–403 (2002).
- Fouladi M. Histone deacetylase inhibitors in cancer therapy. Cancer Invest. 24(5), 521–527 (2006).
- Otsuki A, Patel A, Kasai K et al. Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Mol. Ther. 16(9), 1546–1555 (2008).
- Liu TC, Castelo-Branco P, Rabkin SD, Martuza RL. Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects. Mol. Ther. 16(6), 1041–1047 (2008).
- Kurozumi K, Hardcastle J, Thakur R et al. Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61. Mol. Ther. 16(8), 1382–1391 (2008).
- Haseley A, Boone S, Wojton J et al. Extracellular matrix protein CCN1 limits oncolytic efficacy in glioma. Cancer Res. 72(6), 1353–1362 (2012).
- Wojton J, Kaur B. Impact of tumor microenvironment on oncolytic viral therapy. Cytokine Growth Factor Rev. 21(2–3), 127–134 (2010).
- Kurozumi K, Hardcastle J, Thakur R et al. Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J. Natl Cancer Inst. 99(23), 1768–1781 (2007).
- Zhang W, Fulci G, Buhrman JS et al. Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma. Mol. Ther. 20(1), 37–45 (2012).
- Todo T, Rabkin SD, Chahlavi A, Martuza RL. Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy. Hum. Gene Ther. 10(17), 2869–2878 (1999).
- Parker JN, Gillespie GY, Love CE, Randall S, Whitley RJ, Markert JM. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc. Natl Acad. Sci. USA 97(5), 2208–2213 (2000).
- Andreansky S, He B, van Cott J et al. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther. 5(1), 121–130 (1998).
Website
- ClinicalTrials.gov.www.clinicaltrials.gov